One criticism of CMS’s Oncology Care Model is that providers’ costs are compared with targeted costs that are based partly on their spending from 2012 to 2015, the OCM baseline period. When the actual costs come in below the targeted costs, that earns providers a performance-based payment. But with so many costly oncology therapies launching after the baseline period, this is making it hard for providers to gain a performance-based payment.
- People on the Move
- Medicare and Medicaid
- Datapoint, Drug Benefits
- Headlines in the News
- Abstract, Medicare and Medicaid